Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Appointment of Senior Executive of the Company

Time:2024-04-25

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2024 Second Extraordinary General Meeting

Time:2024-04-24

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Phase III Clinical Trial of TG-1000 Capsules Meeting the Primary Endpoint

Time:2024-04-17

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2024 Second Extraordinary General Meeting

Time:2024-04-02

Ad hoc announcement pursuant to Art. 53 LR -JCARE Announcement on Re-appointment of Auditor

Time:2024-04-02

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on The Change of Supervisor and The Nomination of Candidate For Supervisor

Time:2024-04-02

Ad hoc announcement pursuant to Art. 53 LR -JCARE Announcement on the 2023 Profit Distribution Plan of the Company

Time:2024-04-02

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Approval Notice for Clinical Trial On Drug

Time:2024-02-22

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Drug Clinical Trial Approval for Semaglutide Injection

Time:2024-02-05

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Signing of Long-term Loan Agreement between the Company and International Finance Corporation

Time:2024-01-29

< 1...8910...16 >